BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 27297868)

  • 1. A New Anti-CXCR4 Antibody That Blocks the CXCR4/SDF-1 Axis and Mobilizes Effector Cells.
    Broussas M; Boute N; Akla B; Berger S; Beau-Larvor C; Champion T; Robert A; Beck A; Haeuw JF; Goetsch L; Bailly C; Dumontet C; Matthes T; Corvaia N; Klinguer-Hamour C
    Mol Cancer Ther; 2016 Aug; 15(8):1890-9. PubMed ID: 27297868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
    Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
    PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
    Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
    Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4/SDF-1.
    Mirandola L; Apicella L; Colombo M; Yu Y; Berta DG; Platonova N; Lazzari E; Lancellotti M; Bulfamante G; Cobos E; Chiriva-Internati M; Chiaramonte R
    Leukemia; 2013 Jul; 27(7):1558-66. PubMed ID: 23354012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting primary acute myeloid leukemia with a new CXCR4 antagonist IgG1 antibody (PF-06747143).
    Zhang Y; Saavedra E; Tang R; Gu Y; Lappin P; Trajkovic D; Liu SH; Smeal T; Fantin V; De Botton S; Legrand O; Delhommeau F; Pernasetti F; Louache F
    Sci Rep; 2017 Aug; 7(1):7305. PubMed ID: 28779088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis.
    Teng F; Tian WY; Wang YM; Zhang YF; Guo F; Zhao J; Gao C; Xue FX
    J Hematol Oncol; 2016 Feb; 9():8. PubMed ID: 26851944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melittin inhibits tumor angiogenesis modulated by endothelial progenitor cells associated with the SDF-1α/CXCR4 signaling pathway in a UMR-106 osteosarcoma xenograft mouse model.
    Qin G; Chen Y; Li H; Xu S; Li Y; Sun J; Rao W; Chen C; Du M; He K; Ye Y
    Mol Med Rep; 2016 Jul; 14(1):57-68. PubMed ID: 27177128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
    Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
    J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists.
    Hu Y; Gale M; Shields J; Garron C; Swistak M; Nguyen TH; Jacques G; Fogle R; Siders W; Kaplan J
    Leuk Lymphoma; 2012 Jan; 53(1):130-8. PubMed ID: 21740294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD138-negative myeloma cells regulate mechanical properties of bone marrow stromal cells through SDF-1/CXCR4/AKT signaling pathway.
    Wu D; Guo X; Su J; Chen R; Berenzon D; Guthold M; Bonin K; Zhao W; Zhou X
    Biochim Biophys Acta; 2015 Feb; 1853(2):338-47. PubMed ID: 25450979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of LY2510924, a novel cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models.
    Peng SB; Zhang X; Paul D; Kays LM; Gough W; Stewart J; Uhlik MT; Chen Q; Hui YH; Zamek-Gliszczynski MJ; Wijsman JA; Credille KM; Yan LZ
    Mol Cancer Ther; 2015 Feb; 14(2):480-90. PubMed ID: 25504752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier.
    Chen L; Li L; Zhou C; Chen X; Cao Y
    Mol Carcinog; 2020 Apr; 59(4):390-398. PubMed ID: 32037613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
    Beider K; Darash-Yahana M; Blaier O; Koren-Michowitz M; Abraham M; Wald H; Wald O; Galun E; Eizenberg O; Peled A; Nagler A
    Mol Cancer Ther; 2014 May; 13(5):1155-69. PubMed ID: 24502926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
    Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
    Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells.
    Lee BC; Lee TH; Avraham S; Avraham HK
    Mol Cancer Res; 2004 Jun; 2(6):327-38. PubMed ID: 15235108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SDF-1 in multiple myeloma tumor microenvironment.
    Bouyssou JM; Ghobrial IM; Roccaro AM
    Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.
    Beider K; Begin M; Abraham M; Wald H; Weiss ID; Wald O; Pikarsky E; Zeira E; Eizenberg O; Galun E; Hardan I; Engelhard D; Nagler A; Peled A
    Exp Hematol; 2011 Mar; 39(3):282-92. PubMed ID: 21138752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer.
    Xiang J; Hurchla MA; Fontana F; Su X; Amend SR; Esser AK; Douglas GJ; Mudalagiriyappa C; Luker KE; Pluard T; Ademuyiwa FO; Romagnoli B; Tuffin G; Chevalier E; Luker GD; Bauer M; Zimmermann J; Aft RL; Dembowsky K; Weilbaecher KN
    Mol Cancer Ther; 2015 Nov; 14(11):2473-85. PubMed ID: 26269605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Curcumin exhibits anti-tumor effect and attenuates cellular migration via Slit-2 mediated down-regulation of SDF-1 and CXCR4 in endometrial adenocarcinoma cells.
    Sirohi VK; Popli P; Sankhwar P; Kaushal JB; Gupta K; Manohar M; Dwivedi A
    J Nutr Biochem; 2017 Jun; 44():60-70. PubMed ID: 28402926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvianolic acid B inhibits SDF-1α-stimulated cell proliferation and migration of vascular smooth muscle cells by suppressing CXCR4 receptor.
    Pan CH; Chen CW; Sheu MJ; Wu CH
    Vascul Pharmacol; 2012; 56(1-2):98-105. PubMed ID: 22166584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.